Search results for "FDA Update"

Results 1 - 10 of about 72 for "FDA Update".
Sort by: Relevance | Newest | Oldest

New medication approved for primary biliary cholangitis

The FDA recently approved elafibranor oral tablets (Iqirvo) for primary biliary cholangitis.
28 Jun 2024

Data show higher-than-expected rates of duodenoscope contamination

While the number of medical device reports associated with patient infections has declined by 62% since peaking in 2015, the FDA and duodenoscope manufacturers continue to address issues around device reprocessing.
28 Dec 2018

Automated reprocessors validated for use in specific duodenoscopes

The FDA had requested validation testing data from all companies that have automated endoscope reprocessors labeled to reprocess endoscopes because of the potential association with patient infection.
27 Apr 2018

New data show even higher rates of duodenoscope contamination

The FDA is exploring additional steps to reduce contamination rates, which were higher in postmarket surveillance studies than the agency initially anticipated.
26 Apr 2019

Laxatives and antacids recalled due to microbial contamination

The recall includes several lots of milk of magnesia and magnesium hydroxide/aluminum hydroxide/simethicone sold to clinics and hospitals nationwide.
24 Jun 2022

FDA restricts use of liver disease drug in certain patients

The agency added new warnings to the prescribing information for obeticholic acid, including a contraindication in patients with primary biliary cholangitis and advanced cirrhosis.
25 Jun 2021

Marketing authorized for endoscopic sleeve gastroplasty systems

The systems are the first to be authorized by the FDA for the minimally invasive weight-loss procedure, which is intended for adults with obesity who have not been able to lose weight or maintain weight loss through measures such as diet and exercise.
26 Aug 2022

Laxative recalled due to potential microbial contamination

A company recently recalled one lot of senna syrup, which was distributed to a wholesaler, due to potential microbial contamination.
28 Jan 2022

First immunotherapy approved for initial treatment of gastric cancer

Nivolumab (Opdivo) is approved in combination with certain types of chemotherapy for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
23 Apr 2021

Ranitidine recalled due to nitrosamine impurity

American Health Packaging recalled 11 lots of the histamine-2 receptor antagonist due to the potential presence of excess amounts of N-nitrosodimethylamine, a probable carcinogen.
27 Mar 2020

Result Page: Prev   1   2   3   4   5   6   7   8   Next